To advance therapeutics:
Precision, adaptive and effective therapies

Inoviem is a Bioanalytical company, specialising in Translational Ex-vivo Pharmacology.

We have established platforms working on diseased tissues and delivering experimentally validated clinical Mode of Action, target engagement, and predictive biomarkers through clinically relevant patient stratification.

Accelerating and securing the drug development process

We use complex human biology to develop better, targeted treatments. Our 12 years of experience in personalized medicine allows us to:

  • Increased relevance: we use relevant patient tissue indicating directly  patient response to potential drugs, providing a more accurate picture of efficacy and safety compared to traditional models. This can save time and resources by identifying ineffective options earlier.
  • Improved clinical trial design: we incorporate patient perspectives and experiences into trial design leads to more meaningful endpoints and assessments, making trials more relevant to actual patient outcomes.
  • De-risking the pipeline: We understand drug mechanisms through patient-derived materials. This allows early identification of potential issues, saving resources and reducing the risk of late-stage failures.

From human complexity to personalized insights: our state-of-the-art technology platforms

We embrace the complexity of human biology to develop precision therapies. Our technology platforms, NPOT and PIMS, directly engage diseased human tissues unlocking personalized insights that were previously unattainable.

News, events & resources

See more resources

Need Help